



(43) International Publication Date
14 May 2015 (14.05.2015)

(10) International Publication Number
WO 2015/069888 A3

(51) International Patent Classification:
A61K 31/145 (2006.01)

(21) International Application Number:
PCT/US2014/064336

(22) International Filing Date:
6 November 2014 (06.11.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/900,772 6 November 2013 (06.11.2013) US

(71) Applicant: **RAPTOR PHARMACEUTICALS INC.**
[US/US]; 7 Hamilton Landing, Suite 100, Novato, CA
94949 (US).

(72) Inventors: **RIOUX, Patrice**; 7 Hamilton Landing, Suite
100, Novato, CA 94949 (US). **ZANKEL, Todd, C.**; 6930
California Street, San Francisco, CA 94121 (US).

(74) Agent: **NEVILLE, Katherine, L.**; Marshall, Gerstein &
Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower,
Chicago, IL 60606-6357 (US).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG,
MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM,
PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC,
SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ,
TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU,
TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE,
DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU,
LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK,
SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:
12 November 2015

(54) Title: USE OF CYSTEAMINE AND DERIVATIVES THEREOF TO TREAT MITOCHONDRIAL DISEASES

(57) Abstract: The present disclosure is directed to methods for treating inherited or acquired mitochondrial disease using a cysteamine product, e.g., cysteamine or cystamine or derivatives thereof. It is contemplated that administration of the cysteamine product increases levels of free thiols in mitochondrial disease patients, which can improve the detrimental effects of respiratory chain dysfunction in patients. It is understood that such inherited or acquired mitochondrial disorders are due to inherited or acquired mutations in mitochondrial DNA or nuclear DNA used in mitochondria activity.



WO 2015/069888 A3